1. Show article details.

    New Results From COSMIC-HF Presented At AHA 2019 Show Treatment Of Heart Failure Patients With Omecamtiv Mecarbil Was Associated With Neutral Or Improved Measures Of Diastolic Function

    PR Newswire – 9:00 AM ET 11/18/2019

    THOUSAND OAKS, Calif.

  2. Show article details.

    New Results From COSMIC-HF Presented at AHA 2019 Show Treatment of Heart Failure Patients With Omecamtiv Mecarbil Was Associated With Neutral or Improved Measures of Diastolic Function

    GlobeNewswire – 9:00 AM ET 11/18/2019

    THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif. and SURESNES, France, Nov. 18, 2019 -- Amgen (AMGN), Cytokinetics, Incorporated (CYTK) and Servier announced that new results from COSMIC-HF, a Phase 2 trial evaluating omecamtiv mecarbil in patients with heart failure with reduced ejection fraction, will be presented today at the American Heart Association’s Scientific Sessions 2019 in Philadelphia.

  3. Show article details.

    Amgen Announces New FOURIER Analysis Showing Benefit Of Repatha® (evolocumab) In High-Risk Patients Who Have Experienced A Recent Heart Attack

    PR Newswire – 9:00 AM ET 11/16/2019

    THOUSAND OAKS, Calif. "Nearly 1 in 5 patients will have a recurrent CV event during the first year after a heart attack which makes that year a critical time for high-risk patients1," said Robert Giugliano, M.D., FOURIER executive committee member and a senior investigator at the TIMI Study Group at Brigham and Women's Hospital and Professor of Medicine at Harvard Medical School.

  4. Show article details.

    FTC makes Celgene's Otezla divestiture official condition for Bristol-Myers acquisition

    MarketWatch – 5:43 PM ET 11/15/2019

    Celgene Corp. (CELG) is required to divest its most popular psoriasis treatment in order to be acquired by Bristol- Myers Squibb Co. (BMY), the Federal Trade Commission announced Friday. For Bristol-Myers to close on its $74 billion acquisition, Celgene (CELG) will have to sell its drug Otezla for $13.4 billion to Amgen Inc. (AMGN), the FTC said. "The Commission has ordered BMS to divest Otezla to preserve BMS's incentive to continue developing its own oral product for treating moderate-to-severe...

  5. Show article details.

    BRIEF-Bristol-Myers Squibb Receives Clearance From U.S. FTC For Celgene Acquisition

    Reuters – 4:59 PM ET 11/15/2019

    Bristol-Myers Squibb Co (BMY): * BRISTOL-MYERS SQUIBB RECEIVES CLEARANCE FROM U.S. FEDERAL TRADE COMMISSION FOR CELGENE ACQUISITION. * Bristol-Myers Squibb Co (BMY) - TRANSACTION EXPECTED TO CLOSE ON NOVEMBER 20, 2019. * Bristol-Myers Squibb Co (BMY) - FTC APPROVES AGREEMENT BETWEEN CELGENE AND AMGEN TO DIVEST OTEZLA. * Bristol-Myers Squibb Co (BMY) - HAS NOW SATISFIED ALL REGULATORY APPROVALS FOR CELGENE ACQUISITION.

  6. Show article details.

    Bristol-Myers Squibb Receives Clearance from U.S. Federal Trade Commission for Celgene Acquisition

    Business Wire – 4:55 PM ET 11/15/2019

    Company Has Now Satisfied All Regulatory Approvals for Celgene Acquisition Transaction Expected to Close on November 20, 2019 FTC Approves Agreement between Celgene (CELG) and Amgen (AMGN) to Divest OTEZLA® Bristol-Myers Squibb Company (BMY) announced today that the U.S. Federal Trade Commission has accepted the proposed consent order in connection with the pending merger of Bristol-Myers Squibb (BMY) and Celgene Corpor...

  7. Show article details.

    BRIEF-Amgen And The Duke Clinical Research Institute Begin CVMOBIUS Study

    Reuters – 10:09 AM ET 11/15/2019

    Amgen Inc (AMGN): * AMGEN AND THE DUKE CLINICAL RESEARCH INSTITUTE ANNOUNCE INITIATION OF FIRST LARGE-SCALE REGISTRY TO EVALUATE REAL-WORLD LIPID MANAGEMENT AND THE EFFECTIVENESS OF PCSK9 INHIBITORS. * Amgen Inc (AMGN) - CVMOBIUS STUDY WILL BEGIN PATIENT ENROLLMENT THIS MONTH.

  8. Show article details.

    Amgen And The Duke Clinical Research Institute Announce Initiation Of First Large-Scale Registry To Evaluate Real-World Lipid Management And The Effectiveness Of PCSK9 Inhibitors

    PR Newswire – 9:00 AM ET 11/15/2019

    THOUSAND OAKS, Calif. The cvMOBIUS study will be conducted across the U.S. and Canada and will begin patient enrollment this month. "Cardiovascular disease is one of the most significant public health issues facing our country today.

  9. Show article details.

    China's BeiGene gets FDA approval for drug to treat rare form of lymphoma

    Reuters – 5:06 PM ET 11/14/2019

    The U.S. Food and Drug Administration on Thursday approved BeiGene Ltd's lymphoma treatment, validating the China-based drugmaker's strategy of largely using data from trials held outside the United States to file for approval. The company tested the treatment, Brukinsa, in 118 patients with mantle cell lymphoma enrolled in two studies.

  10. Show article details.

    FOCUS-Biotech-for-hire PeptiDream charts new path and becomes short target

    Reuters – 9:22 PM ET 11/13/2019

    * PeptiDream (PPTDF) has been darling of Tokyo stock market. * Partners to develop drugs for clinical trials. * Short-seller Muddy Waters says investors 'deluded' By Rocky Swift. The promise of PeptiDream Inc's (PPTDF) drug-discovery technology and its lucrative research-for-hire contracts have made it a darling of the Tokyo stock market.

  11. Show article details.

    FOCUS-Biotech-for-hire PeptiDream charts new path and becomes short target

    Reuters – 8:58 AM ET 11/13/2019

    * PeptiDream (PPTDF) has been darling of Tokyo stock market. * Partners to develop drugs for clinical trials. * Short-seller Muddy Waters says investors 'deluded' By Rocky Swift. The promise of PeptiDream Inc's (PPTDF) drug-discovery technology and its lucrative research-for-hire contracts have made it a darling of the Tokyo stock market.

  12. Show article details.

    BRIEF-Amgen Highlights Data To Be Presented At AHA 2019 Across Cardiovascular Portfolio

    Reuters – 9:15 AM ET 11/11/2019

    Amgen Inc (AMGN): * AMGEN HIGHLIGHTS DATA TO BE PRESENTED AT AHA 2019 ACROSS CARDIOVASCULAR PORTFOLIO. * Amgen Inc (AMGN) - NEW PHASE 2 DATA FROM OMECAMTIV MECARBIL COSMIC-HF STUDY TO BE PRESENTED IN ORAL SESSION Source text for Eikon: Further company coverage:

  13. Show article details.

    Amgen Highlights Data To Be Presented At AHA 2019 Across Cardiovascular Portfolio

    PR Newswire – 9:00 AM ET 11/11/2019

    THOUSAND OAKS, Calif.

  14. Show article details.

    Amgen To Present At The 28th Annual Credit Suisse Healthcare Conference

    PR Newswire – 5:01 PM ET 11/07/2019

    THOUSAND OAKS, Calif. About AmgenAmgen (AMGN) is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. Amgen (AMGN) focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives.

  15. Show article details.

    Novartis gets U.S. nod for long-delayed Amgen copycat

    Reuters – 4:59 AM ET 11/05/2019

    * Copy targets Amgen's (AMGN) $4 bln-per-year Neulasta. * FDA delay helped rivals beat Novartis to market. By John Miller. Novartis on Tuesday won U.S. approval for its long-delayed version of Amgen's (AMGN) $4 billion seller Neulasta drug, helping the Swiss drugmaker in its uphill battle to sell copies of rivals' blockbusters in the world's top drug market.

  16. Show article details.

    BRIEF-Revolution Medicines And Amgen Partner On Phase 1B Study To Evaluate Combination Of Rmc-4630 And Amg 510

    Reuters – 8:32 AM ET 11/04/2019

    Amgen Inc (AMGN): * REVOLUTION MEDICINES AND AMGEN PARTNER ON PHASE 1B STUDY TO EVALUATE COMBINATION OF RMC-4630 AND AMG 510. * REVOLUTION MEDICINES - AGREEMENT WITH AMGEN TO EVALUATE COMBINATION OF RMC-4630 AND AMG 510.

  17. Show article details.

    Facebook and Alphabet stocks in trouble over antitrust fears, warns Goldman

    MarketWatch – 12:44 PM ET 11/01/2019

    Earnings continue to take center stage on Friday, ably supported by the twists and turns of the U.S.-China trade war. Renewed trade fears sent stocks retreating on Thursday, while mixed corporate earnings failed to inspire investors. Oil majors Exxon and Chevron (CVX), consumer goods giant Colgate-Palmolive (CL) and Chinese e-commerce giant Alibaba (BABA) will be in focus as they report third quarter results ahead of the open.

  18. Show article details.

    BRIEF-AbbVie Says Doesn't View Any Change In Humira Pricing Going Into 2020

    Reuters – 10:08 AM ET 11/01/2019

    AbbVie Inc (ABBV): * ABBVIE SAYS LAUNCH OF PSORIASIS DRUG SKYRIZI "IS GOING EXTREMELY WELL" AND COMMERCIAL ACCESS FOR THE DRUG IS AT MORE THAN 80% - CONF. CALL. * ABBVIE SEES "VERY LITTLE CANNIBALIZATION" TO HUMIRA SALES FROM ITS NEW RHEUMATOID ARTHRITIS DURG RINVOQ - CONF. CALL.

  19. Show article details.

    Deals of the day-Mergers and acquisitions

    Reuters – 6:14 AM ET 11/01/2019

    The following bids, mergers, acquisitions. ** Amgen Inc (AMGN) said on Thursday it will take a 20.5% stake in BeiGene Ltd to expand the California-based biotechnology company's presence in China, the world's second-largest pharmaceuticals market.

  20. Show article details.

    Amgen To Invest In Chinese Biotech -- WSJ

    DJ Business News – 2:47 AM ET 11/01/2019

    This article is being republished as part of our daily reproduction of WSJ.com articles that also appeared in the U.S. print edition of The Wall Street Journal. U.S. drugmaker Amgen Inc. (AMGN) said it is buying a roughly 20% stake in a Chinese biotechnology company for $2.7 billion in cash, further demonstrating China's emergence as a key market for foreign pharmaceutical companies. Amgen (AMGN) said BeiGene Ltd. (BGNE), a Beijing-based company focused on oncology, is going to commercialize...

Page:

Today's and Upcoming Events

  • Jan
    27

    AMGN to announce Q4 earnings (Unconfirmed)

Past Events (last 90 days)

  • Nov
    14

    AMGN ex-Dividend for $1.45 on 11/14/2019

    • Announce Date: 10/22/2019
    • Record Date: 11/15/2019
    • Pay Date: 12/06/2019
  • Oct
    29

    AMGN announced Q3 earnings.

Data provided by Thomson Reuters © 2019

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.